EUVIMEDEUVIMED entdecken
Übersichtsarbeit

How real is the thrombotic risk with the rebalancing agents used to treat hemophilia?

Michael Makris

Journal of Thrombosis and Haemostasis · 2026-06 · 24 (6) · 2040-2042

DOI: 10.1016/j.jtha.2026.03.012 ↗

Kurz gefasst

Übersichtsarbeit in der Zeitschrift Journal of Thrombosis and Haemostasis, 2026-06. Verfasst von Michael Makris. Beteiligte Einrichtung: School of Medicine and Population Health, University of Sheffield, Sheffield, UK. Electronic address: m.makris@sheffield.ac.uk. Die Arbeit nennt 16 Literaturangaben.

AbstractBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Kein Abstract verfügbar.

Autor:innen und Institutionen

  • School of Medicine and Population Health, University of Sheffield, Sheffield, UK. Electronic address: m.makris@sheffield.ac.uk.

Zitieren

APA

Makris, M. (2026). How real is the thrombotic risk with the rebalancing agents used to treat hemophilia?. Journal of Thrombosis and Haemostasis, 24(6), 2040-2042. https://doi.org/10.1016/j.jtha.2026.03.012

Vancouver

Makris M. How real is the thrombotic risk with the rebalancing agents used to treat hemophilia?. Journal of Thrombosis and Haemostasis. 2026;24(6):2040-2042. doi:10.1016/j.jtha.2026.03.012

BibTeX
@article{Makris2026,
  author = {Makris, Michael},
  title = {How real is the thrombotic risk with the rebalancing agents used to treat hemophilia?},
  journal = {Journal of Thrombosis and Haemostasis},
  year = {2026},
  volume = {24},
  number = {6},
  pages = {2040--2042},
  doi = {10.1016/j.jtha.2026.03.012}
}
Kostenlos starten →